| Name | Title | Contact Details |
|---|
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs
Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. The wide-ranging disease risk predictions provided by Nightingale consist of two interconnected factors: The extensive blood analysis technology developed by Nightingale and a large amount of data on health events. Nightingale helps people make better personal health decisions and connects the health industry to offer their services for individuals preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone. We`re a team of 60 members––a diverse bunch with interdisciplinary expertise in business, marketing, computational medicine, data science, healthcare, IT, design and more––who envisage a world that focuses on keeping people healthy rather than just treating illnesses. So, if you are looking to enable good tech that could make a real difference, Nightingale is the place to be
Agrivida is developing and commercializing solutions that are the next evolutionary step in animal nutrition, using the plant as a factory to produce and deliver highly differentiated products. We are transforming the economics of enzyme and animal feed production through our use of plant-expressed enzymes and plant modification to develop transformational products for monogastric and ruminant animal nutrition.
Revolutionizing Proteomics To Transform Healthcare SomaLogic was founded in 2000 with the goal of improving the well-being and quality of life of every individual by transforming how diseases were detected and diagnosed. Building on the previous decade of aptamer research, SomaLogic scientists have developed a new proteomics technology that overcomes the significant challenges of current technologies, and which has multiple applications across the biological and medical sciences. Our mission is to leverage our proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare.